X

Clinical Trials

Contact Us

A171601 (Age 75 and older. 70-74 y.o. cohort is closed to accrual)

Study Number: A171601 (Age 75 and older. 70-74 y.o. cohort is closed to accrual)

This phase II trial studies the side effects and how well palbociclib and letrozole or fulvestrant works in treating patients aged 75 years and older with estrogen receptor positive, HER2 negative breast cancer that has spread to other places in the body. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as letrozole or fulvestrant, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib and letrozole or fulvestrant may work better in treating patients with breast cancer. The trial will explore factors other than chronologic age that can affect toxicity rates as identified using a cancer-specific geriatric assessment.

Contact Person(s)
  • MBMC, Chris Sanders, 314-996-5802

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.